CARLSBAD, Calif., Oct. 27, 2015 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will
host a live webcast on Tuesday, November
3 at 8:00 a.m. Eastern Time to
review ISIS-TTRRx data presented at the 1st
European Congress of Hereditary ATTR Amyloidosis and provide Phase
3 development plan update.
Interested parties may listen to the call by dialing
877-443-5662 or access the webcast at www.isispharm.com. A
webcast replay will be available for a limited time at the same
address.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases.
Using its proprietary antisense technology, Isis has created a
large pipeline of first-in-class or best-in-class drugs, with over
a dozen drugs in mid- to late-stage development. Drugs
currently in Phase 3 development include volanesorsen, a drug Isis
is developing and plans to commercialize through its wholly owned
subsidiary, Akcea Therapeutics, to treat patients with familial
chylomicronemia syndrome and familial partial lipodystrophy;
ISIS-TTRRx, a drug Isis is developing with GSK to treat
patients with all forms of TTR amyloidosis; and
ISIS-SMNRx, a drug Isis is developing with Biogen to
treat infants and children with spinal muscular atrophy.
Isis' patents provide strong and extensive protection for its drugs
and technology. Additional information about Isis is
available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This
press release includes forward-looking statements regarding Isis
Pharmaceuticals' financial position and outlook, Isis' business,
and the therapeutic and commercial potential of Isis' technologies
and products in development. Any statement describing Isis'
goals, expectations, financial or other projections, intentions or
beliefs is a forward-looking statement and should be considered an
at-risk statement. Such statements are subject to certain
risks and uncertainties, particularly those inherent in the process
of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. Isis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking
statements. Although Isis' forward-looking statements reflect
the good faith judgment of its management, these statements are
based only on facts and factors currently known by Isis. As a
result, you are cautioned not to rely on these forward-looking
statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31,
2014, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Isis Pharmaceuticals, Inc. KYNAMRO® is a
registered trademark of Genzyme Corporation.
Logo -
http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-host-webcast-to-review-isis-ttr-rx-data-presented-at-1st-european-congress-of-hereditary-attr-amyloidosis-and-provide-phase-3-development-plan-update-300166397.html
SOURCE Isis Pharmaceuticals, Inc.